About: Prevalence of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases
Creator	Ramírez, Julio Aguirre, Rodrigo Blanco, Francisco Blanco, Ricardo Castrejón, Isabel Galindo, María Gonzalez, Antonio Manrique-Arija, Sara Mena-Vázquez, Natalia Mera-Varela, Antonio Pablos, José Retuerto, Miriam González-Gay, Miguel Abasolo-Alcázar, Lydia Arribas, Guillermo Cañete, Juan De, Francisco Fernández-Fernández, David Fernández-Gutierrez, Benjamín Gómez-Puerta, Jose León-Mateos, Leticia Rodríguez-Rodríguez, Luis Seijas-Lopez, Álvaro
Source	MedRxiv
abstract	ABSTRACT Background. The susceptibility of patients with rheumatic diseases, and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. Methods. We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with SARS-CoV-2 positive PCR tests performed in the hospital to the same reference populations. Incidences of PCR+ confirmed COVID-19 were compared among groups. Results. Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Systemic autoimmune or immune mediated diseases (AI/IMID) patients showed a significant increase, whereas inflammatory arthritis (IA) or systemic lupus erythematosus (SLE) patients did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. IA patients on targeted-synthetic or biological disease-modifying antirheumatic drugs (ts/bDMARD), but not those on conventional-synthetic (csDMARD), had a greater prevalence despite a similar age distribution. Conclusion. Patients with AI/IMID show a variable risk of hospital diagnosed COVID-19. Interplay of aging, therapies, and disease specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyze the specific factors involved in COVID-19 susceptibility.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1101/2020.05.11.20097808
has license	medrxiv
sha1sum (hex)	9b62193f278ef828f6ae2c531ecf029da2d58d43
schema:url	https://doi.org/10.1101/2020.05.11.20097808
resource representing a document's title	Prevalence of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases
resource representing a document's body	covid:9b62193f278ef828f6ae2c531ecf029da2d58d43#body_text
is schema:about of	named entity 'risks' named entity 'Chronic' named entity 'Patients' named entity 'COVID-19' named entity 'CHRONIC' named entity 'PATIENTS' named entity 'COVID-19' named entity 'rheumatic diseases' named entity 'COVID-19' named entity 'Prevalence' named entity 'Covid-19' named entity 'older age' named entity 'COVID-19' named entity '12 de Octubre' named entity 'peer review' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'higher risk' named entity 'COVID-19' named entity 'sarcoidosis' named entity 'odds ratios' named entity 'SARS-CoV-2' named entity 'anti-inflammatory' named entity 'Spain' named entity '2.9 million' named entity '2.9 million' named entity 'rheumatology' named entity 'immunosuppressive drugs' named entity 'methotrexate' named entity 'immunosuppressed' named entity 'PCR' named entity 'Odds ratio' named entity 'peer review' named entity 'IMID' named entity 'microbiology' named entity 'SARS-CoV-2' named entity 'MAS' named entity 'medRxiv' named entity 'emergency departments' named entity 'SARS-CoV-2' named entity 'CAR-T' named entity 'biological agent' named entity 'representative sample' named entity 'ICU' named entity 'leflunomide' named entity 'odds ratios' named entity 'Hospital General Universitario Gregorio Marañón' named entity 'non-parametric' named entity 'COVID' named entity 'systemic inflammatory' named entity 'infection' named entity 'odds ratios' named entity 'clinical practice' named entity 'antimalarials' named entity 'statistical analyses' named entity 'pandemics' named entity 'medRxiv' named entity 'peer review' named entity 'antimalarials' named entity 'chronic inflammatory' named entity 'IMID' named entity 'COVID' named entity 'European Regional Development Fund'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software